

NOFO Outcome Tables

1. Table 1 Short-term outcome: Increased access to harm reduction services and supplies
2. Table 2 Short-term outcome: Increased HCV, HIV, and HBV testing among SSP Participants
3. Table 3 Short-term outcome: Increased prevention and treatment of infections associated with injection drug use
4. Table 4 Intermediate outcomes: Increased use of harm reduction services by PWID, Decreased incidence of unsafe injection practices, Increased hepatitis C viral clearance among SSP participants with hepatitis C

1. Short-term outcome: Increased access to harm reduction services and supplies (N=62)

	Total Count Across all Funded SSPs: n (%)
SSP Location	
Number of SSPs in the Midwest	
Number of SSPs in the Northeast	
Number of SSPs in the South	
Number of SSPs in the West	
SSP Service Delivery Model (# of SSPs for each)	
Brick and mortar fixed site (including drop-in centers)	
Backpack/outreach or foot/pedestrian-based	
Pop-up sites (tables, tent, etc.)	
Delivery to regular locations (e.g., established route)	
Delivery to participant requested locations (e.g., home delivery)	
Mail-based distribution	
Vending machine	
SSP Syringe Distribution Policies (# of SSPs for each)	
One-for-one exchange (1:1)	
One-for-one (1:1) plus (i.e., "rounding up" 1:1)	
One-for-one exchange (1:1) with starter packs	
One-for-one (1:1) plus with starter packs	
Need-based	
SSP Serving Specific Demographics of Participants (# of SSPs for each)	
Lesbian, gay, bisexual, or queer persons	
Transgender, genderqueer, or non-binary persons	
Women	
American Indian or Alaska Native persons	
Asian persons	
Black or African-American persons	
Hispanic or Latinx persons	
Native Hawaiian or Other Pacific Islander persons	
Persons aged < 20 years	
Persons aged 20 to 29 years	
Persons aged 30 to 39 years	

Persons aged 40 to 59 years	
Persons aged < or = 60 years	
Persons who trade sex	

2. Short-term outcome: Increased HCV, HIV, and HBV testing among SSP Participants (N=62)

	Total Count Across all Funded SSPs: n (%)
Number of SSP participants screened for hepatitis C	
Number of SSP participants screened for hepatitis B	
Number of SSP participants screened for HIV	

3. Short-term outcome: Increased prevention and treatment of infections associated with injection drug use (N=62)

	Total Count Across all Funded SSPs: n (%)
SSP participants with hepatitis C	
Number of participants referred for hepatitis C treatment	
Number of participants provided onsite hepatitis C treatment	
SSP participants with HIV	
Number of participants referred for antiretroviral therapy	
Number of participants provided onsite antiretroviral therapy	
SSP participants who are HIV negative	
Number of participants referred for PrEP	
Number of participants provided onsite PrEP	
Number of SSP participants receiving hepatitis A vaccination	
Number of SSP participants receiving hepatitis B vaccination	

4. Intermediate outcomes (N=62)

	Total Count Across all Funded SSPs: n (%)
Increased use of harm reduction services by PWID	
Number of participant visits	
Decreased incidence of unsafe injection practices	
Number of syringes distributed	
Increased hepatitis C viral clearance among SSP participants with hepatitis C	
Number of SSP participants attaining sustained viral clearance of hepatitis C	